A Phase III Randomized, Double Blind Placebo Controlled Trial To Evaluate the Non-interference in the Immune Response of Three Doses of ORV 116E to Antigens Contained in Childhood Vaccines and to Assess the Clinical Lot Consistency of Three Production Lots

Trial Profile

A Phase III Randomized, Double Blind Placebo Controlled Trial To Evaluate the Non-interference in the Immune Response of Three Doses of ORV 116E to Antigens Contained in Childhood Vaccines and to Assess the Clinical Lot Consistency of Three Production Lots

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs ORV 116E (Primary)
  • Indications Rotavirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top